Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation

Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?

(2019) Shalin Kothari et al.   Current Hematologic Malignancy Reports

Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1

(2019) H. Pfeifer et al.   LEUKEMIA

Comparison of Population-Based Observational Studies With Randomized Trials in Oncology

(2019) Payal D. Soni et al.   JOURNAL OF CLINICAL ONCOLOGY

Chronic myeloid leukemia stem cells

(2019) Mohammad Houshmand et al.   LEUKEMIA

Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma

(2019) Susan Bal et al.   BRITISH JOURNAL OF HAEMATOLOGY

Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy

(2019) Zachariah DeFilipp et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians

(2019) J. Gauthier et al.   BONE MARROW TRANSPLANTATION

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances

(2019) Irene Della Starza et al.   Frontiers in Oncology

BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee

(2018) Sarah A. Holstein et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

(2018) Gerrit J. Schuurhuis et al.   BLOOD

Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches

(2018) Ciprian Tomuleasa et al.   CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES

Effect of More vs Less Frequent Follow-up Testing on Overall and Colorectal Cancer–Specific Mortality in Patients With Stage II or III Colorectal Cancer

(2018) Peer Wille-Jørgensen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Association Between Intensity of Posttreatment Surveillance Testing and Detection of Recurrence in Patients With Colorectal Cancer

(2018) Rebecca A. Snyder et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000)

(2018) Martin Schrappe et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Minimal Residual Disease in Acute Myeloid Leukemia

(2018) Mojca Jongen-Lavrencic et al.   NEW ENGLAND JOURNAL OF MEDICINE

MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment

(2018) Ola Landgren et al.   SEMINARS IN HEMATOLOGY

The challenging task of enumerating blasts in the bone marrow

(2018) Aaron Hodes et al.   SEMINARS IN HEMATOLOGY

Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

(2018) Sebastian Giebel et al.   BONE MARROW TRANSPLANTATION

How good are we at predicting the fate of someone with acute myeloid leukaemia?

(2017) E Estey et al.   LEUKEMIA

Measurable residual disease testing in acute myeloid leukaemia

(2017) C S Hourigan et al.   LEUKEMIA

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

(2017) J Flores-Montero et al.   LEUKEMIA

Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia

(2017) Carolyn Owen et al.   LEUKEMIA & LYMPHOMA

Minimal Residual Disease Eradication in CML: Does It Really Matter?

(2017) Srinivas K. Tantravahi et al.   Current Hematologic Malignancy Reports

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia

(2016) Prisca Theunissen et al.   BLOOD

Effect of measurable (‘minimal’) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia

(2016) M Othus et al.   LEUKEMIA

Best Practices in Chronic Myeloid Leukemia Monitoring and Management

(2016) Simona Soverini et al.   ONCOLOGIST

Minimal Residual Disease and Childhood Leukemia: Standard of Care Recommendations From the Pediatric Oncology Group of Ontario MRD Working Group

(2016) Uma H. Athale et al.   PEDIATRIC BLOOD & CANCER

Quantifying the impact of different approaches for handling continuous predictors on the performance of a prognostic model

(2016) Gary S. Collins et al.   STATISTICS IN MEDICINE

Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL

(2015) P. A. Thompson et al.   BLOOD

Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies

(2015) J. J. M. van Dongen et al.   BLOOD

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial

(2014) Ajay Vora et al.   LANCET ONCOLOGY

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

(2013) S. H. Petersdorf et al.   BLOOD

High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study

(2013) Monique Terwijn et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial

(2013) Ajay Vora et al.   LANCET ONCOLOGY

Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks

(2013) Paul Blanche et al.   STATISTICS IN MEDICINE

The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

(2012) Jan J. Cornelissen et al.   Nature Reviews Clinical Oncology

Evaluating Prognostic Accuracy of Biomarkers under Competing Risk

(2011) Yingye Zheng et al.   BIOMETRICS